Published in Mol Biol Cell on September 01, 1998
Insulin-like growth factor-binding protein-5 (IGFBP-5): a critical member of the IGF axis. Biochem J (2006) 1.77
Regulation of muscle mass by growth hormone and IGF-I. Br J Pharmacol (2008) 1.44
Insulin-like growth factor-I regulation of immune function: a potential therapeutic target in autoimmune diseases? Pharmacol Rev (2010) 1.39
Insulin-like growth factor-binding protein-5 inhibits osteoblast differentiation and skeletal growth by blocking insulin-like growth factor actions. Mol Endocrinol (2008) 1.01
Functional roles and clinical values of insulin-like growth factor-binding protein-5 in different types of cancers. Chin J Cancer (2012) 1.01
Insulin-like growth factor-binding protein-2 is required for osteoclast differentiation. J Bone Miner Res (2012) 0.95
Differences in gene expression between strabismic and normal human extraocular muscles. Invest Ophthalmol Vis Sci (2012) 0.86
Integrated data analysis reveals uterine leiomyoma subtypes with distinct driver pathways and biomarkers. Proc Natl Acad Sci U S A (2016) 0.78
IGFBP-5 Promotes Fibrosis Independently of Its Translocation to the Nucleus and Its Interaction with Nucleolin and IGF. PLoS One (2015) 0.75
The smooth muscle cell. II. Growth of smooth muscle in culture and formation of elastic fibers. J Cell Biol (1971) 10.72
Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev (1995) 9.54
Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell (1991) 8.99
Molecular modeling of protein-glycosaminoglycan interactions. Arteriosclerosis (1989) 5.88
Betaglycan presents ligand to the TGF beta signaling receptor. Cell (1993) 3.48
Heparan sulphate bound growth factors: a mechanism for stromal cell mediated haemopoiesis. Nature (1988) 3.22
The binding of vascular endothelial growth factor to its receptors is dependent on cell surface-associated heparin-like molecules. J Biol Chem (1992) 2.85
Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques. J Clin Invest (1993) 2.60
Compartmentalization of a haematopoietic growth factor (GM-CSF) by glycosaminoglycans in the bone marrow microenvironment. Nature (1987) 2.40
Analysis of serum insulin-like growth factor binding proteins using western blotting: use of the method for titration of the binding proteins and competitive binding studies. Anal Biochem (1986) 2.30
Insulin-like growth factor binding protein 1 stimulates cell migration and binds to the alpha 5 beta 1 integrin by means of its Arg-Gly-Asp sequence. Proc Natl Acad Sci U S A (1993) 1.85
Extracellular matrix contains insulin-like growth factor binding protein-5: potentiation of the effects of IGF-I. J Cell Biol (1993) 1.64
Thrombospondins. Methods Enzymol (1994) 1.53
Evidence for a functional role of endogenously produced somatomedinlike peptides in the regulation of DNA synthesis in cultured human fibroblasts and porcine smooth muscle cells. J Clin Invest (1985) 1.43
Insulin-like growth factor binding proteins. Vitam Horm (1993) 1.33
Binding of insulin-like growth factor (IGF) I or II to IGF-binding protein-2 enables it to bind to heparin and extracellular matrix. Endocrinology (1996) 1.07
Insulin-like growth factor binding proteins in maternal serum throughout gestation and in the puerperium: effects of a pregnancy-associated serum protease activity. J Clin Endocrinol Metab (1990) 1.06
Insulin-like growth factor-I (IGF-I) regulates IGF-binding protein-5 synthesis through transcriptional activation of the gene in aortic smooth muscle cells. J Biol Chem (1996) 1.04
Identification of the forms of insulin-like growth factor-binding proteins produced by human fibroblasts and the mechanisms that regulate their secretion. J Biol Chem (1992) 0.98
A comparison of three heparin-binding serine proteinase inhibitors. J Biol Chem (1992) 0.96
Protease-resistant form of insulin-like growth factor-binding protein 5 is an inhibitor of insulin-like growth factor-I actions on porcine smooth muscle cells in culture. J Clin Invest (1997) 0.95
Insulin-like growth factor binding protein-5 binds to plasminogen activator inhibitor-I. Endocrinology (1997) 0.95
Human fibroblasts secrete a serine protease that cleaves insulin-like growth factor-binding protein-5. Endocrinology (1994) 0.94
Properties of an insulin-like growth factor-binding protein-4 protease that is secreted by smooth muscle cells. Endocrinology (1995) 0.94
Efficient DNA transfection of quiescent mammalian cells using poly-L-ornithine. Nucleic Acids Res (1993) 0.91
Substitution of specific amino acids in insulin-like growth factor (IGF) binding protein 5 alters heparin binding and its change in affinity for IGF-I response to heparin. J Biol Chem (1996) 0.89
Identification of the extracellular matrix binding sites for insulin-like growth factor-binding protein 5. J Biol Chem (1996) 0.89
Crinopexy: extracellular regulation of growth factor action. Kidney Int Suppl (1995) 0.86
In vivo proteolysis of serum insulin-like growth factor (IGF) binding protein-3 results in increased availability of IGF to target cells. J Clin Invest (1994) 0.85
The ontogeny and regulation of a 31,000 molecular weight insulin-like growth factor-binding protein in fetal porcine plasma and sera. Endocrinology (1988) 0.81
A factor contained in plasma is required for IGF binding protein-1 to potentiate the effect of IGF-I on smooth muscle cell DNA synthesis. J Cell Physiol (1990) 0.78
Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet (2000) 24.22
Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev (1995) 9.54
The Scottish Record Linkage System. Health Bull (Edinb) (1993) 8.06
Mechanical and chemical unfolding of a single protein: a comparison. Proc Natl Acad Sci U S A (1999) 7.74
Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res (1996) 5.38
North of England evidence based guidelines development project: guideline for the primary care management of dementia. BMJ (1998) 4.39
The SV40 enhancer is composed of multiple functional elements that can compensate for one another. Cell (1986) 4.25
A human IFNGR1 small deletion hotspot associated with dominant susceptibility to mycobacterial infection. Nat Genet (1999) 3.12
Trends in hospital necropsy rates: Scotland 1961-74. Br Med J (1977) 3.09
Atomic force microscopy reveals the mechanical design of a modular protein. Proc Natl Acad Sci U S A (2000) 3.04
Clinical uses of insulin-like growth factor I. Ann Intern Med (1994) 2.93
A study of cells present in peripheral lymph of pigs with special reference to a type of cell resembling the Langerhans cell. Cell Tissue Res (1979) 2.85
Non-adherent, low-density cells from human peripheral blood contain dendritic cells and monocytes, both with veiled morphology. Immunology (1986) 2.72
The invisible women in dentistry. Br Dent J (1995) 2.66
Ultrasensitive magnetic biosensor for homogeneous immunoassay. Proc Natl Acad Sci U S A (2000) 2.52
Role of veiled cells in lymphocyte activation. Eur J Immunol (1982) 2.50
Measuring outcomes: one month survival after acute myocardial infarction in Scotland. Heart (1996) 2.30
Can non-mechanical proteins withstand force? Stretching barnase by atomic force microscopy and molecular dynamics simulation. Biophys J (2001) 2.25
Recommendations for nomenclature of the insulin-like growth factor binding protein superfamily. J Clin Endocrinol Metab (1998) 2.17
Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med (2000) 2.16
Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet (2001) 2.08
A putative transforming gene of Jijoye virus differs from that of Epstein-Barr virus prototypes. Virology (1985) 2.07
Use of recombinant granulocyte-colony stimulating factor to treat neutropenia occurring during craniospinal irradiation. Int J Radiat Oncol Biol Phys (1993) 2.05
Gender-specific changes in bone turnover and skeletal architecture in igfbp-2-null mice. Endocrinology (2008) 2.03
Chlamydia trachomatis: opportunistic screening in primary care. Br J Gen Pract (2001) 2.01
Effect of the cholesterol content of small unilamellar liposomes on their stability in vivo and in vitro. Biochem J (1980) 1.97
Hormonal control of immunoreactive somatomedin production by cultured human fibroblasts. J Clin Invest (1981) 1.92
Mapping the folding pathway of an immunoglobulin domain: structural detail from Phi value analysis and movement of the transition state. Structure (2001) 1.89
Insulin-like growth factor binding protein 1 stimulates cell migration and binds to the alpha 5 beta 1 integrin by means of its Arg-Gly-Asp sequence. Proc Natl Acad Sci U S A (1993) 1.85
Relationship between dose, distance and time in Sonic Hedgehog-mediated regulation of anteroposterior polarity in the chick limb. Development (1997) 1.82
Contact tracing--where do we go from here? Sex Transm Infect (1998) 1.81
The somatomedins: a family of insulinlike hormones under growth hormone control. Recent Prog Horm Res (1974) 1.76
The structure of a PKD domain from polycystin-1: implications for polycystic kidney disease. EMBO J (1999) 1.75
Burns after photodynamic therapy. BMJ (2000) 1.74
Towards a complete description of the structural and dynamic properties of the denatured state of barnase and the role of residual structure in folding. J Mol Biol (2000) 1.74
Insights from the sharp end of intravenous medication errors: implications for infusion pump technology. Qual Saf Health Care (2005) 1.73
Overcoming language difficulties with migrant patients. Med J Aust (1979) 1.72
Mortality in patients of the Glasgow Blood Pressure Clinic. J Hypertens (1986) 1.71
Recommendations for nomenclature of the insulin-like growth factor binding protein superfamily. Endocrinology (1998) 1.66
Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol (2013) 1.65
The chronic effects of an extract of Bacopa monniera (Brahmi) on cognitive function in healthy human subjects. Psychopharmacology (Berl) (2001) 1.64
Extracellular matrix contains insulin-like growth factor binding protein-5: potentiation of the effects of IGF-I. J Cell Biol (1993) 1.64
Adherence to antiretroviral therapy among HIV-infected methadone patients: effect of ongoing illicit drug use. Am J Drug Alcohol Abuse (2000) 1.64
The folding of an immunoglobulin-like Greek key protein is defined by a common-core nucleus and regions constrained by topology. J Mol Biol (2000) 1.63
Hepatitis C disease among injection drug users: knowledge, perceived risk and willingness to receive treatment. Drug Alcohol Depend (2001) 1.62
Depression among needle exchange program and methadone maintenance clients. J Subst Abuse Treat (2000) 1.58
An insulin-like growth factor (IGF) binding protein enhances the biologic response to IGF-I. Proc Natl Acad Sci U S A (1987) 1.57
Identification of two DNA-binding sites on the globular domain of histone H5. EMBO J (1996) 1.57
Measurement of anti-DNA antibodies: a reappraisal using five different methods. Ann Rheum Dis (1987) 1.53
Amyotrophic lateral sclerosis in South-East England: a population-based study. The South-East England register for amyotrophic lateral sclerosis (SEALS Registry). Neuroepidemiology (2007) 1.52
Characterization of residual structure in the thermally denatured state of barnase by simulation and experiment: description of the folding pathway. Proc Natl Acad Sci U S A (1997) 1.51
Comparison of "accelerated" tissue plasminogen activator with streptokinase for treatment of suspected myocardial infarction. Med Decis Making (1996) 1.51
Inhaled steroids in patients with bronchiectasis. Respir Med (1992) 1.51
A new study of bacterial motion: superconducting quantum interference device microscopy of magnetotactic bacteria. Biophys J (1999) 1.51
An enhanced microsatellite map of diploid Fragaria. Theor Appl Genet (2006) 1.49
Explorations of the insulinlike and growth-promoting properties of somatomedin by membrane receptor assays. Adv Metab Disord (1975) 1.49
Artificial pacing by electrode catheter for heart block or asystole complicating acute myocardial infarction. Br Heart J (1966) 1.49
The effect of boundary selection on the stability and folding of the third fibronectin type III domain from human tenascin. Biochemistry (1998) 1.49
Recombinant human insulin-like growth factor I increases insulin sensitivity and improves glycemic control in type II diabetes. Diabetes (1996) 1.49
The topography of metabolic deficits in posterior cortical atrophy (the visual variant of Alzheimer's disease) with FDG-PET. J Neurol Neurosurg Psychiatry (2003) 1.48
Effects of caloric or protein restriction on insulin-like growth factor-I (IGF-I) and IGF-binding proteins in children and adults. J Clin Endocrinol Metab (1995) 1.47
Ligand occupancy of the alpha-V-beta3 integrin is necessary for smooth muscle cells to migrate in response to insulin-like growth factor. Proc Natl Acad Sci U S A (1996) 1.46
The insulin-like growth factors. Annu Rev Physiol (1993) 1.44
Evidence for a functional role of endogenously produced somatomedinlike peptides in the regulation of DNA synthesis in cultured human fibroblasts and porcine smooth muscle cells. J Clin Invest (1985) 1.43
Physical assault in New Zealand: the experience of 21 year old men and women in a community sample. N Z Med J (1998) 1.42
Developing senior doctors as mentors: a form of continuing professional development. Report Of an initiative to develop a network of senior doctors as mentors: 1994-99. Med Educ (2000) 1.40
Assessing the dietetic needs of different patient groups receiving enteral tube feeding in primary care. J Hum Nutr Diet (2002) 1.40
Epidural blood patch is contraindicated in HIV-positive patients. Proposer. Int J Obstet Anesth (1994) 1.38
SQUID-based microwave cavity search for dark-matter axions. Phys Rev Lett (2010) 1.36
A universal biosensing platform based on optical micro-ring resonators. Biosens Bioelectron (2007) 1.33
Structure and stability of an immunoglobulin superfamily domain from twitchin, a muscle protein of the nematode Caenorhabditis elegans. J Mol Biol (1996) 1.33
Blocking ligand occupancy of the alphaVbeta3 integrin inhibits insulin-like growth factor I signaling in vascular smooth muscle cells. Proc Natl Acad Sci U S A (1998) 1.32
Cooperative binding of the globular domains of histones H1 and H5 to DNA. Nucleic Acids Res (1992) 1.31
HIV/AIDS patients' perspectives on adhering to regimens containing protease inhibitors. J Gen Intern Med (1998) 1.30
The isolation and characterization of the glycopeptides from horseradish peroxidase isoenzyme C. Biochim Biophys Acta (1976) 1.29
Cytomegalovirus granulomatous hepatitis. Am J Med (1979) 1.29
Exchange of histones H1 and H5 between chromatin fragments. A preference of H5 for higher-order structures. Eur J Biochem (1983) 1.28
Cultured fibroblast monolayers secrete a protein that alters the cellular binding of somatomedin-C/insulinlike growth factor I. J Clin Invest (1986) 1.27
Elevated levels of insulin-like growth factor-binding protein-2 in the serum of prostate cancer patients. J Clin Endocrinol Metab (1993) 1.26
Asymptomatic herpes simplex virus shedding from the genital tract whilst on suppressive doses of oral acyclovir. Int J STD AIDS (1990) 1.25
Thrombospondin and osteopontin bind to insulin-like growth factor (IGF)-binding protein-5 leading to an alteration in IGF-I-stimulated cell growth. Endocrinology (2000) 1.25
Hepsin, a cell surface serine protease identified in hepatoma cells, is overexpressed in ovarian cancer. Cancer Res (1997) 1.23
Two proteins with the same structure respond very differently to mutation: the role of plasticity in protein stability. J Mol Biol (2000) 1.22
An enzyme(s) that converts glutaminyl-peptides into pyroglutamyl-peptides. Presence in pituitary, brain, adrenal medulla, and lymphocytes. J Biol Chem (1987) 1.21
A retrospective observational study examining the characteristics and outcomes of tumours diagnosed within and without of the English NHS Bowel Cancer Screening Programme. Br J Cancer (2012) 1.21
Alcohol use patterns predict high-risk HIV behaviors among active injection drug users. J Subst Abuse Treat (2000) 1.21
Conservation of folding and stability within a protein family: the tyrosine corner as an evolutionary cul-de-sac. J Mol Biol (2000) 1.20
Insulin-like growth factors (IGF) in muscle development. Expression of IGF-I, the IGF-I receptor, and an IGF binding protein during myoblast differentiation. J Biol Chem (1989) 1.20
Insulin-like growth factor (IGF)-binding proteins inhibit the smooth muscle cell migration responses to IGF-I and IGF-II. Endocrinology (1995) 1.20
Roles of phosphatidylinositol 3-kinase and mitogen-activated protein kinase pathways in stimulation of vascular smooth muscle cell migration and deoxyriboncleic acid synthesis by insulin-like growth factor-I. Endocrinology (1999) 1.19
Competitive binding of somatomedin to the insulin receptors of adipocytes, chondrocytes, and liver membranes. Proc Natl Acad Sci U S A (1972) 1.18
Hormonal and nutritional regulation of IGF-I and its binding proteins. Horm Res (1994) 1.18
Fine needle aspiration cytology, with immediate reporting, in the outpatient diagnosis of breast disease. Ann R Coll Surg Engl (1987) 1.18
Cell migration: interactions among integrins, IGFs and IGFBPs. Prog Growth Factor Res (1995) 1.16